Brokerages Set Boston Scientific Corporation (NYSE:BSX) Price Target at $71.62

Boston Scientific Corporation (NYSE:BSX) has earned a consensus recommendation of “Moderate Buy” from the thirty-one brokerages that are covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell recommendation, five have issued a hold recommendation and twenty-four have issued a buy recommendation on the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $71.4615.

Several equities analysts recently issued reports on the stock. Stifel Nicolaus set a $60.00 price objective on shares of Boston Scientific in a research note on Wednesday, July 29th. Raymond James Financial reaffirmed an “outperform” rating and issued a $57.00 price objective on shares of Boston Scientific in a research report on Thursday, July 30th. Citigroup dropped their target price on Boston Scientific from $70.00 to $61.00 and set a “buy” rating for the company in a research note on Thursday, July 30th. Bank of America decreased their price target on Boston Scientific from $105.00 to $68.00 and set a “buy” rating on the stock in a research note on Monday, May 18th. Finally, Barclays lowered their price target on Boston Scientific from $96.00 to $89.00 and set an “overweight” rating for the company in a report on Thursday, May 28th.

Boston Scientific News Roundup

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific reported progress in its RESPI clinical study, which is evaluating wearable technology for breathing monitoring. The update supports the company’s longer-term innovation pipeline, although it is not expected to materially affect near-term revenue. Boston Scientific’s RESPI Study Signals Progress in Wearable Breathing Monitoring
• Positive Sentiment: BTIG Research maintained a Buy rating while reducing its price target from $60 to $56. The revised target still implies substantial upside from recent trading levels, indicating the analyst views the cyberattack disruption as manageable over time. BTIG Research price-target update
• Neutral Sentiment: Recent commentary is examining whether investors should buy or sell BSX puts, reflecting elevated uncertainty and volatility following the earnings warning rather than a new fundamental development. BSX Stock: Is It Time To Buy Or Sell Puts?
• Negative Sentiment: Boston Scientific said it is unlikely to meet its 2026 net-sales growth and EPS guidance. The cyberattack disrupted manufacturing and order shipments worldwide and is expected to materially affect both third-quarter and full-year results, driving the recent decline in shares. Boston Scientific says cyberattack likely to hurt 2026 sales and profit
• Negative Sentiment: Analysts also cited pressure on Boston Scientific’s WATCHMAN and electrophysiology businesses. While product launches and cost savings may support recovery by 2028, the combination of weaker near-term demand and cybersecurity-related disruption increases execution risk. Boston Scientific’s 2026 Growth Outlook Weakens

Insider Buying and Selling

In other news, Director Edward J. Ludwig bought 5,000 shares of Boston Scientific stock in a transaction that occurred on Friday, July 31st. The shares were purchased at an average price of $45.48 per share, for a total transaction of $227,400.00. Following the completion of the acquisition, the director owned 30,359 shares of the company’s stock, valued at $1,380,727.32. The trade was a 19.72% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Michael F. Mahoney purchased 186,240 shares of the stock in a transaction on Monday, August 3rd. The shares were purchased at an average cost of $48.33 per share, with a total value of $9,000,979.20. Following the transaction, the chief executive officer owned 1,590,024 shares of the company’s stock, valued at $76,845,859.92. This trade represents a 13.27% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders purchased 194,522 shares of company stock valued at $9,385,210. Insiders own 0.34% of the company’s stock.

Hedge Funds Weigh In On Boston Scientific

Hedge funds and other institutional investors have recently modified their holdings of the company. Brighton Jones LLC increased its position in Boston Scientific by 0.8% during the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock worth $2,445,000 after purchasing an additional 226 shares in the last quarter. FWL Investment Management LLC acquired a new stake in shares of Boston Scientific in the second quarter worth $26,000. Main Street Financial Solutions LLC increased its position in shares of Boston Scientific by 35.3% in the second quarter. Main Street Financial Solutions LLC now owns 7,556 shares of the medical equipment provider’s stock worth $812,000 after acquiring an additional 1,971 shares in the last quarter. Ieq Capital LLC raised its stake in shares of Boston Scientific by 97.0% in the 2nd quarter. Ieq Capital LLC now owns 123,592 shares of the medical equipment provider’s stock valued at $13,275,000 after acquiring an additional 60,860 shares during the period. Finally, HUB Investment Partners LLC raised its stake in shares of Boston Scientific by 56.2% in the 2nd quarter. HUB Investment Partners LLC now owns 7,102 shares of the medical equipment provider’s stock valued at $763,000 after acquiring an additional 2,556 shares during the period. 89.07% of the stock is owned by institutional investors and hedge funds.

Boston Scientific Price Performance

Shares of NYSE:BSX opened at $45.04 on Friday. Boston Scientific has a one year low of $42.20 and a one year high of $108.07. The company has a 50-day simple moving average of $47.08 and a 200-day simple moving average of $54.97. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24. The stock has a market capitalization of $65.27 billion, a price-to-earnings ratio of 18.23, a PEG ratio of 1.04 and a beta of 0.57.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The firm had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. During the same period in the previous year, the business earned $0.75 earnings per share. The company’s revenue for the quarter was up 7.5% compared to the same quarter last year. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, analysts predict that Boston Scientific will post 3.3 EPS for the current year.

Boston Scientific announced that its board has initiated a stock buyback program on Monday, May 18th that authorizes the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization authorizes the medical equipment provider to repurchase up to 6.4% of its shares through open market purchases. Shares repurchase programs are usually a sign that the company’s board believes its shares are undervalued.

About Boston Scientific

Boston Scientific Corporation is a medical device company that develops, manufactures and markets products used in minimally invasive procedures. Its technologies are designed to diagnose and treat a range of medical conditions while supporting less invasive alternatives to traditional surgery.

The company’s products address cardiovascular, endoscopy, urology, pelvic health and neuromodulation applications. Its portfolio includes devices used in cardiac rhythm management and electrophysiology, structural heart procedures, peripheral and vascular interventions, gastrointestinal procedures, kidney stone and prostate treatments, and therapies for chronic pain and other neurological conditions.

Founded in 1979, Boston Scientific serves healthcare providers and patients in markets around the world.